- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Laidlaw stuft Aeon Biopharma mit "Buy" ein: Aktie mit erheblichem Kurspotenzial | 2 | Investing.com Deutsch | ||
| 09.09. | Laidlaw initiates Aeon Biopharma stock coverage with buy rating | 4 | Investing.com | ||
| 24.08. | AEON Biopharma Inc: AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer | 430 | GlobeNewswire (Europe) | - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory... ► Artikel lesen | |
| 19.08. | AEON Biopharma Inc: AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX | 462 | GlobeNewswire (Europe) | - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed... ► Artikel lesen | |
| 17.08. | H.C. Wainwright senkt Kursziel für Aeon Biopharma Aktie wegen Verwässerung | 1 | Investing.com Deutsch | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.08. | H.C. Wainwright cuts Aeon Biopharma stock price target on dilution | 2 | Investing.com | ||
| 13.08. | AEON Biopharma Q2 Non-GAAP EPS of -$0.02 | 1 | Seeking Alpha | ||
| 12.08. | AEON Biopharma Inc: AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 206 | GlobeNewswire (Europe) | - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program... ► Artikel lesen | |
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | AEON Biopharma regains NYSE American listing compliance after $13.6M offering | 1 | Seeking Alpha | ||
| 03.08. | AEON Biopharma Inc: AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | 130 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX... ► Artikel lesen | |
| 23.07. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | AEON Biopharma prices $13.75M offering with milestone warrants | 1 | Seeking Alpha | ||
| 14.07. | AEON Biopharma Inc: AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | 221 | GlobeNewswire (Europe) | IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)... ► Artikel lesen | |
| 09.07. | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.07. | AEON Biopharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 17.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | AEON Biopharma Inc: AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| ABIVAX | 90,75 | -2,89 % | Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | ||
| ALTERITY THERAPEUTICS | 0,258 | 0,00 % | ALTERITY THERAPEUTICS LTD - S-8, Securities to be offered to employees in employee benefit plans | ||
| APTEVO THERAPEUTICS | 1,840 | 0,00 % | Aptevo Therapeutics: Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO)... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,023 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Biocure Technology Inc. (CURE.X) | Le 13 août/August 2026
Trading in the shares of Biocure Technology Inc. (CURE.X) will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen |
Das Unternehmen AEON BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,007 (+2,94 %) liegt der Kurs bei 0,248 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.